Mutual of America Capital Management LLC Trims Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mutual of America Capital Management LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 172,277 shares of the biopharmaceutical company's stock after selling 5,121 shares during the period. Mutual of America Capital Management LLC's holdings in Gilead Sciences were worth $15,913,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Flputnam Investment Management Co. boosted its holdings in Gilead Sciences by 9.3% in the fourth quarter. Flputnam Investment Management Co. now owns 5,772 shares of the biopharmaceutical company's stock valued at $533,000 after purchasing an additional 490 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Gilead Sciences by 7.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 3,007 shares of the biopharmaceutical company's stock valued at $278,000 after buying an additional 217 shares during the period. Shoker Investment Counsel Inc. boosted its stake in shares of Gilead Sciences by 1.5% in the fourth quarter. Shoker Investment Counsel Inc. now owns 22,649 shares of the biopharmaceutical company's stock worth $2,092,000 after buying an additional 345 shares during the last quarter. Wakefield Asset Management LLLP acquired a new stake in Gilead Sciences during the fourth quarter worth about $514,000. Finally, QRG Capital Management Inc. raised its position in Gilead Sciences by 7.1% during the fourth quarter. QRG Capital Management Inc. now owns 258,585 shares of the biopharmaceutical company's stock valued at $23,885,000 after acquiring an additional 17,141 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Up 2.1 %

Shares of GILD opened at $114.31 on Friday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $114.77. The firm has a market capitalization of $142.46 billion, a P/E ratio of 308.95, a P/E/G ratio of 0.71 and a beta of 0.18. The firm has a 50-day moving average price of $97.42 and a 200 day moving average price of $89.94. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.76%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is currently 854.05%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 8,500 shares of the business's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $91.96, for a total value of $781,660.00. Following the sale, the chief financial officer now directly owns 132,373 shares in the company, valued at approximately $12,173,021.08. The trade was a 6.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 293,356 shares of company stock valued at $29,166,240 in the last quarter. Insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of analyst reports. Robert W. Baird raised their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a "neutral" rating in a research note on Thursday, November 7th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a research report on Thursday, February 13th. Truist Financial upped their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research report on Friday, November 8th. Wells Fargo & Company raised their target price on Gilead Sciences from $105.00 to $120.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Finally, Citigroup initiated coverage on Gilead Sciences in a research note on Thursday, November 14th. They issued a "buy" rating and a $125.00 price target for the company. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $102.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.